137 related articles for article (PubMed ID: 35950222)
1. HEG1 as a novel potential biomarker for the prognosis of lung adenocarcinoma.
Zou X; Zhang Y; Wang N; Shi J; Li Q; Hao W; Zhu W; Han W
Cancer Med; 2023 Feb; 12(3):3288-3298. PubMed ID: 35950222
[TBL] [Abstract][Full Text] [Related]
2. The High Expression of PTPRH Is Associated with Poor Prognosis of Human Lung Adenocarcinoma.
Chen A; Ding S; Shen X; Lin X
Comput Math Methods Med; 2021; 2021():9932088. PubMed ID: 34367321
[TBL] [Abstract][Full Text] [Related]
3. Prognostic value of SEC61G in lung adenocarcinoma: a comprehensive study based on bioinformatics and in vitro validation.
Zheng Q; Wang Z; Zhang M; Yu Y; Chen R; Lu T; Liu L; Ma J; Liu T; Zheng H; Li H; Li J
BMC Cancer; 2021 Nov; 21(1):1216. PubMed ID: 34774014
[TBL] [Abstract][Full Text] [Related]
4. Cancer/testis antigen HEMGN correlated with immune infiltration serves as a prognostic biomarker in lung adenocarcinoma.
Jiang Y; Yu L; Hu Q; Kang Y; You J; Huang C; Xu X; Chen L
Mol Immunol; 2023 Jan; 153():226-237. PubMed ID: 36563642
[TBL] [Abstract][Full Text] [Related]
5. Overexpression of CENPF is associated with progression and poor prognosis of lung adenocarcinoma.
Li MX; Zhang MY; Dong HH; Li AJ; Teng HF; Liu AL; Xu N; Qu YQ
Int J Med Sci; 2021; 18(2):494-504. PubMed ID: 33390818
[No Abstract] [Full Text] [Related]
6. Effect of PTGES3 on the Prognosis and Immune Regulation in Lung Adenocarcinoma.
Jiang W; Wei Q; Xie H; Wu D; He H; Lv X
Anal Cell Pathol (Amst); 2023; 2023():4522045. PubMed ID: 37416927
[TBL] [Abstract][Full Text] [Related]
7. High Expression of
Deng H; Huang Y; Wang L; Chen M
Biomed Res Int; 2020; 2020():2071593. PubMed ID: 33134373
[TBL] [Abstract][Full Text] [Related]
8. Identification of a novel therapeutic candidate, NRK, in primary cancer-associated fibroblasts of lung adenocarcinoma microenvironment.
Wei T; Song J; Liang K; Li L; Mo X; Huang Z; Chen G; Mao N; Yang J
J Cancer Res Clin Oncol; 2021 Apr; 147(4):1049-1064. PubMed ID: 33387038
[TBL] [Abstract][Full Text] [Related]
9. Elevated PHD2 expression might serve as a valuable biomarker of poor prognosis in lung adenocarcinoma, but no lung squamous cell carcinoma.
Xu XL; Gong Y; Zhao DP
Eur Rev Med Pharmacol Sci; 2018 Dec; 22(24):8731-8739. PubMed ID: 30575913
[TBL] [Abstract][Full Text] [Related]
10. PYCR1 knockdown inhibits the proliferation, migration, and invasion by affecting JAK/STAT signaling pathway in lung adenocarcinoma.
Gao Y; Luo L; Xie Y; Zhao Y; Yao J; Liu X
Mol Carcinog; 2020 May; 59(5):503-511. PubMed ID: 32133692
[TBL] [Abstract][Full Text] [Related]
11. Elevated FAM83A expression predicts poorer clincal outcome in lung adenocarcinoma.
Zhang J; Sun G; Mei X
Cancer Biomark; 2019; 26(3):367-373. PubMed ID: 31594212
[TBL] [Abstract][Full Text] [Related]
12. DPYSL2 as potential diagnostic and prognostic biomarker linked to immune infiltration in lung adenocarcinoma.
Wu YJ; Nai AT; He GC; Xiao F; Li ZM; Tang SY; Liu YP; Ai XH
World J Surg Oncol; 2021 Sep; 19(1):274. PubMed ID: 34517904
[TBL] [Abstract][Full Text] [Related]
13. NPM1 Is a Prognostic Biomarker Involved in Immune Infiltration of Lung Adenocarcinoma and Associated With m6A Modification and Glycolysis.
Liu XS; Zhou LM; Yuan LL; Gao Y; Kui XY; Liu XY; Pei ZJ
Front Immunol; 2021; 12():724741. PubMed ID: 34335635
[TBL] [Abstract][Full Text] [Related]
14. SNCA correlates with immune infiltration and serves as a prognostic biomarker in lung adenocarcinoma.
Zhang X; Wu Z; Ma K
BMC Cancer; 2022 Apr; 22(1):406. PubMed ID: 35421944
[TBL] [Abstract][Full Text] [Related]
15. Identification and prognostic biomarkers among ZDHHC4/12/18/24, and APT2 in lung adenocarcinoma.
Bian J; Xiong W; Yang Z; Li M; Song D; Zhang Y; Liu C
Sci Rep; 2024 Jan; 14(1):522. PubMed ID: 38177255
[TBL] [Abstract][Full Text] [Related]
16. H2A Histone Family Member Z (H2AFZ) Serves as a Prognostic Biomarker in Lung Adenocarcinoma: Bioinformatic Analysis and Experimental Validation.
Li Z; Hu M; Qiu J; Feng J; Zhang R; Wu H; Hu G; Ren J
Med Sci Monit; 2022 Jan; 28():e933447. PubMed ID: 35027526
[TBL] [Abstract][Full Text] [Related]
17. High expression of RRM2 as an independent predictive factor of poor prognosis in patients with lung adenocarcinoma.
Jin CY; Du L; Nuerlan AH; Wang XL; Yang YW; Guo R
Aging (Albany NY); 2020 Dec; 13(3):3518-3535. PubMed ID: 33411689
[TBL] [Abstract][Full Text] [Related]
18. SLC2A5 Correlated with Immune Infiltration: A Candidate Diagnostic and Prognostic Biomarker for Lung Adenocarcinoma.
Luo L; Su J; Zheng Y; Huang F; Huang R; Luo H
J Immunol Res; 2021; 2021():9938397. PubMed ID: 34604392
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of clinical value and potential mechanism of MTFR2 in lung adenocarcinoma via bioinformatics.
Chen C; Tang Y; Qu WD; Han X; Zuo JB; Cai QY; Xu G; Song YX; Ke XX
BMC Cancer; 2021 May; 21(1):619. PubMed ID: 34039308
[TBL] [Abstract][Full Text] [Related]
20. Protein phosphatase 1 regulatory subunit 3G (PPP1R3G) correlates with poor prognosis and immune infiltration in lung adenocarcinoma.
Zhuo X; Chen L; Lai Z; Liu J; Li S; Hu A; Lin Y
Bioengineered; 2021 Dec; 12(1):8336-8346. PubMed ID: 34592886
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
